Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Non-Current Assets: 2010-2025

Historic Non-Current Assets for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $114.0 million.

  • OptimizeRx's Non-Current Assets fell 349.69% to $114.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $462.4 million, marking a year-over-year decrease of 781.16%. This contributed to the annual value of $117.2 million for FY2024, which is 907.49% down from last year.
  • As of Q3 2025, OptimizeRx's Non-Current Assets stood at $114.0 million, which was down 349.69% from $115.2 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Non-Current Assets ranged from a high of $128.9 million in Q4 2023 and a low of $25.4 million during Q1 2022
  • Its 5-year average for Non-Current Assets is $69.1 million, with a median of $36.5 million in 2023.
  • In the last 5 years, OptimizeRx's Non-Current Assets skyrocketed by 25729.9% in 2023 and then crashed by 923.33% in 2025.
  • Over the past 5 years, OptimizeRx's Non-Current Assets (Quarter) stood at $25.9 million in 2021, then skyrocketed by 39.43% to $36.1 million in 2022, then skyrocketed by 257.3% to $128.9 million in 2023, then decreased by 9.07% to $117.2 million in 2024, then decreased by 2.73% to $114.0 million in 2025.
  • Its Non-Current Assets stands at $114.0 million for Q3 2025, versus $115.2 million for Q2 2025 and $116.1 million for Q1 2025.